ShangPharma and Qidong Biopharma Industrial Zone sign an agreement for a $60-million investment in China
The plans include a multifunctional preclinical research facility and a state-of-the-art biologics manufacturing facility.
ShangPharma has announced plans to establish a subsidiary in the Qidong Biopharma Industrial Zone as part of a multistage expansion project for its biologics service portfolio. In the first phase, ShangPharma and Qidong Biopharma Industrial zone will invest 60 million USD to build a comprehensive and multifunctional preclinical research facility, as well as a state-of-the-art biologics manufacturing facility. The preclinical facility will be operated by ShangPharma’s CRO division, ChemPartner and the biologics manufacturing facility will be operated by ShangPharma’s CMO division, China Gateway Biologics. During the construction phase of the manufacturing facility, the company’s existing biologics CMC facility will continue to operate out of its Shanghai site.
The new China Gateway Biologics’ manufacturing facility will provide commercial-scale operations for biopharmaceuticals. It will be comprised one 500-L single-use mammalian cell culture train for clinical phase supply and two 2000-L trains for commercial manufacturing. These capabilities will be complemented with fill & finish capabilities of the appropriate scale.
Michael Hui, CEO of ShangPharma stated: “I am proud that Qidong Biopharma Industrial Zone has selected ShangPharma as partner for the first facility of this kind in Qidong. The investment offers China Gateway Biologics the opportunity to grow to the next level as a full biopharmaceutical service provider from preclinical development to commercial scale. We strongly believe the state-of-the-art single-use facility conforming to Western standards will be able to support our international client base.”
Xu Feng, Qidong’s Party Secretary and Chairman of Qidong Standing Committee of the People’s Congress said: “Choosing ShangPharma as the first tenant for the biopharma zone in Qidong is a big milestone to establish Qidong as a biotech hub at the door steps of Shanghai. ShangPharma/CGB is a strong partner with international focus and the facility will serve as model for other projects of similar scale and needs.”
The biopharmaceutical manufacturing facility shall be operational for the first client project in early 2018.
Related News
-
News Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel
A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to... -
.png)
News Protecting life-saving therapies: CPHI Online Podcast Series
The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.
-
News 2026 Outsourcing Outlook Update - pharma at a crossroads
The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing ... -
News Roche maintains German investment commitment whilst rivals scale back
Pharmaceutical giant Roche has reaffirmed its commitment to investing in Germany, standing firm even as competitors Eli Lilly and Boehringer Ingelheim dramatically reduce their planned investments in response to controversial healthcare reforms.
-
News Women in Pharma: The History of CPHI Women in Japan
Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive. -
News EU drafts deal to end essential medicines shortage
European negotiators have agreed new legislation to tackle persistent shortages of essential medicines by prioritising supply security over price in public procurement and supporting domestic pharmaceutical manufacturing with strategic funding.
-
News Thermo Fisher Scientific offloads microbiology business to PE firm Astorg
The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th... -
News The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026
CPHI Online contributor David Roach takes a look at how conversations around sustainability in the pharmaceutical industry can and must be transformed into actionable deliveries, and what the inaugural CPHI Sustainability Summit means for the industry.